INTRODUCTION
Pleomorphic xanthoastrocytoma (PXA), first described by Kepes et al. [8] in 1979, is a low grade, brain tumor that is thought to arise from the aberrant mitotic activity of sub-pial astrocytes. [8] PXA comprises <1% of all brain tumors and is commonly found in young adults and children, with a peak incidence between 10 and 30 years of age. [6, 10] e vast majority of tumors are found in the supratentorial compartment, with a predilection for the temporal lobes followed by frontal and parietal lobes. e tumors are usually located superficially, often involving the cortex and the leptomeninges, with sparing of the dura. Macroscopically, www.surgicalneurologyint.com
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PXAs tend to be well circumscribed with cystic components. [4] On imaging, these tumors appear as a solid enhancing nodule frequently accompanied by eccentric peripheral cystic components, surrounding edema and a reactive "dural tail" with leptomeningeal involvement. [12] Histologically, these pleomorphic tumors exhibit variable features with spindle cells, multinucleated and fibrillary giant cells, eosinophilic granular bodies, polygonal cells, and lipid-laden xanthomatous astrocytes. [4, 8] Immunohistochemical analysis demonstrates abundant reticulin, glial fibrillary acidic protein (GFAP) and S100 positivity, and variable staining with neuronal markers including synaptophysin, MAP2, and other neurofilaments. [10, 15] Given their predilection for the temporal lobes, many patients with PXA present with progressive headaches or seizures. [6, 12] However, we report an extremely rare patient who was diagnosed with PXA located in the suprasellar cistern of the third ventricle arising from the optic chiasm.
CASE REPORT
A 30-year-old man with a 3-year history of progressive loss of peripheral vision in his right eye was referred to our clinic following the discovery of a suprasellar mass on imaging. He denied any headaches, history of seizures, recent changes in weight, breast discharge, heat or cold intolerance, or changes in shoe size or facial features. His only complaint was a progressive visual field defect in the right upper quadrant of the right eye. He had no significant other medical or surgical history, and, apart from a visual field defect of the right eye (quadrantanopia), he had an otherwise unremarkable physical exam including intact cranial nerves III to XII. Endocrine workup was unremarkable. Magnetic resonance imaging (MRI) with and without contrast of his brain revealed a multilobulated complex mass with both cystic and solid components in the suprasellar region measuring 28.7 mm × 34.5 mm × 37.2 mm (AP by TR by CC) [ Figure 1 ]. e radiological differential diagnosis was craniopharyngioma.
Operation and postoperative course
e patient underwent surgery for the resection of the suprasellar tumor through an endoscopic endonasal transsphenoidal approach. e intraoperative visualization of the tumor showed that the mass appeared to be arising from the optic chiasm rather than the Sella. Furthermore, intraoperative resection was complicated by significant adherence of the tumor capsule to local structures, including the carotid arteries. To prevent damage to the surrounding structures, the operation was concluded with an estimated 50-60% of the tumor resected. Intraoperative frozen pathology sections results revealed nonspecific glial reactive tissue. Postoperatively, the patient remained at neurologic baseline except for a new left lower quadrant visual field defect. He did not have any oculomotor nerve palsy. MRI confirmed expected partial resection of the suprasellar mass as well as the decreased mass effect on surrounding tissues [ Figure 2 ]. e patient's postoperative course was unremarkable, and he was discharged home. Initially, we considered adjuvant radiotherapy for the tumor that was adherent to the chiasm and carotids; however, the patient's case was discussed at our hospital neuro-oncology tumor board (neuro-oncologists, pathologists, neurosurgery, and radiation oncology teams) and given the indolent course of the PXA, a decision was made to follow the patient clinically and with serial imaging and if he had a worsening of his symptoms during the follow-up period to perform radiosurgery then.
At 1-year follow-up, MRI of his brain revealed the stable size of the known residual with no new areas of enhancement and improvement of the tumor local mass effect. e patient endorsed subjective improvement of his vision, and ophthalmologic followup at 1 year revealed partial improvement of his visual fields deficits compared to preoperative evaluation. At 1-year follow-up, the patient was not in any hormonal supplementation.
Pathological analysis
Microscopically, the tumor was consistent with a glial neoplasm with variable morphology. Some cells were spindled, others were within a mucin-rich matrix, and focal cells with lipidized cytoplasm were present. Eosinophilic granular bodies, lymphocytic infiltrates, and Rosenthal fibers were also noted to be present [ Figure 3 ]. Immunohistochemical workup showed the tumor to be GFAP, vimentin and S-100 positive. Synaptophysin immunohistochemistry showed focal weak positivity, and neurofilament stains showed rare entrapped axons. IDH1 was negative, and trichrome staining showed collagen within the tumor. Ki-67 index was <2%. Additional workup showed diffuse CD34 positivity, positive MAP2 staining, and negative BRAF and V600E staining. Based on these findings, [4] a final diagnosis of PXA was made.
DISCUSSION
PXA are a rare form of astrocytic tumor that is commonly found in young adults and children. [4] Although rare, identification or at least suspicion of, PXA can often be made preoperatively on imaging, given its characteristic location and radiographic morphologic features. [6, 12] Although pleomorphic in histology this tumor is considered low grade and has a relatively favorable prognosis. Due to PXA's rarity, including it in the preoperative list of differential diagnoses becomes a significant challenge when the tumor does not behave characteristically, especially if the location on imaging is not the usual. PXA is most commonly found supratentorially, in the cortical regions of the cerebral hemispheres, and typically presents as a cystic mass with a solid, contrast enhancing mural component. [6, 12] Definitive diagnosis relies on histopathological and immunohistochemistry analysis. e pleomorphic and atypical nature of the neoplastic cells makes an intraoperative diagnosis on frozen sections difficult. As such, PXA can be misdiagnosed as high-grade malignant glioma, and the neurosurgeon may not proceed with complete resection when considering the risks and benefits of the procedure. erefore, a strong preoperative suspicion of PXA can significantly aid in intraoperative diagnosis and surgical decision-making. Furthermore, multiple reports cite the extend of resection as one of the strongest predictors of recurrence-free survival. [6, 13] A recent study by Ida et al. [6] showed that a gross total resection at the initial surgery has a recurrencefree survival at 5 years of 85% compared to 45% for a subtotal resection with stereotactic radiosurgery as adjuvant therapy. ese numbers must be taken into consideration for patient and family counseling regarding this type of tumors and in the preoperatively period to prepare for surgery with the goal of a gross total resection.
As our understanding of this tumor changes, new tests are available to further characterize the tumor histologically. e BRAF and V600E mutation, if present, are associated with longer overall survival compared to the tumors that are nonmutant. [6] Additional factors to be considered in PXA histology are the presence of multiple mitotic figures. Researchers at the Mayo Clinic initially proposed that PXA that have 5/10 mitotic index per highpower fields should be consider PXA with anaplastic features. [4] Recently, they were able to provide further proof that this type of PXA with anaplastic features do harbor a worse prognosis as the overall survival is shorter compared to those without anaplastic features. [6] Hence, once the tumor has been resected this additional histologically, and immunohistochemistry tests should be performed to provide additional information for recurrence and overall prognosis for patients with PXA.
As mentioned before PXA is usually a supratentorial tumor with a predisposition to the temporal lobes however, PXA has been sporadically reported to arise in unusual locations including the posterior fossa, spinal cord, and the retina. [5, 11, 17] PXA originating in the suprasellar region is extremely rare and has only been described in six patients in the scientific literature before the case we present here. [2, 7, 9, 14, 16] In Table 1 , we present the summary of the prior 7 cases reported in literature. Review of those reports, in conjunction with this case, seems to suggest that suprasellar PXA tends to occur more frequently in adults rather than children. Furthermore, of the case reports of suprasellar masses [ Table 1 ], the report by Yeh et al. [16] is the only one in a pediatric patient, and the other cases were in adults from 19 to 78 years old with 4 female and 2 male cases.
On imaging, PXA often presents as an enhancing, solid-cystic mass on MRI, and commonly causes visual disturbances as the presenting clinical symptom due to local mass effect. Interestingly, as with our case, the case by Yeh et al. [16] was initially thought to be a craniopharyngioma, and the final postsurgical pathology revealed a PXA. Although uncommon, PXA is a potential differential diagnosis for suprasellar masses with cystic and solid components. e suprasellar PXA reported by Krossnes et al. [9] similarly to our case presented here the tumor originated from the optic chiasm and was growing along the nerves making a total resection high risk for optic nerve damage. As expected, they noticed small areas of enhancement along both optic nerves in their case compatible with residual tumor. [9] As mentioned before by having PXA as a differential diagnosis preoperatively, surgical plan may change to have a more aggressive resection to provide a longer recurrence-free survival. In the larger series of PXAs (74 cases), Ida et al. [6] reported a 64.6% of recurrence free at 5 years for both PXA and PXA with anaplastic features. Although in general PXAs have a favorable outcome, recurrence and disease progression are seen in 15-20% of cases, requiring long-term follow-up especially in cases with a subtotal resection. In our case at 12 months, the patient was free of recurrence, and the known residual tumor was stable in size.
At present, there is not a definite guide to treat PXA that did not have a gross total resection during surgery. As mentioned before in general for all PXA, a gross total resection is one of the most important factors for recurrence-free survival. [6] For subtotal resections only, a handful of report exists for adjuvant therapy and most of them will start once the patient has had a disease recurrence. ere is no current guideline for coadjuvant therapy at the time of surgery for subtotal resection, and most of the treatments are extrapolated from similar tumors histology and grade in the same location. Of the suprasellar PXAs cases available in the scientific literature only the case by Arita et al. [2] had a subtotal resection and coadjuvant stereotactic radiosurgery. In our case given the overall indolent course of the tumor and the improvement of the patient's visual symptoms, we elected to monitor him clinically and with serial MRI of his brain and proceed with adjuvant therapy if new symptoms develop or his vision worsens. Ida et al. [6] proposed that for a tumor that displays anaplastic characteristics adjuvant therapy should be considered right away due to their high frequency of recurrence. ere are some examples of good response in anaplastic PXA to adjuvant therapy [1, 3] On the other hand, if gross total resection is achieved the literature supports that there is no need for immediate coadjuvant therapies.
CONCLUSION
PXA are rare neoplasms, but they should be considered in the differential diagnosis of suprasellar solid-cystic tumors, especially those found in children and young adults. Gross total resection provides the best overall recurrence free for these tumors and should be the initial goal of surgery: coadjuvant therapy can be considered for tumors with anaplastic features.
Declaration of patient consent
Patient consent was not obtained as the patient is covered under the Institutional Review Boards protocol.
Financial support and sponsorship
Nil.
Conflicts of interest
ere are no conflicts of interest. 
